US Pharma MarketingDaiichi Sankyo to give commercial team a makeover; Novo Nordisk
Daiichi Sankyo will retool its commercial organization, and Ken Keller will be at the center of it all as chief commercialization officer. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
→ Daiichi Sankyo will retool its commercial organization, and Ken Keller will be at the center of it all as chief commercialization officer. On April 1, 2027, the Japanese pharma will split the commercialization efforts ...
Source: Endpoints News